<DOC>
	<DOCNO>NCT01894035</DOCNO>
	<brief_summary>This pilot , non-interventional , company-sponsored , multi-center study document observational data patient routine treatment Pulmonary Arterial Hypertension ( PAH ) inhale iloprost ( use I-Neb device inhalation ) . The plan study recruitment time 18 month . The maximum follow period study 12 month . The data collect patient initiated treatment mention ( inhaled iloprost use I-Neb device ) since February 1st , 2013 . Frequency visit procedure perform routine condition . The primary objective study assess compliance patient WHO/NYHA ( World Health Organization/New York Heart Association ) functional Class III Pulmonary Arterial Hypertension treat Inhaled Iloprost clinical practice , use I-neb Insight tool .</brief_summary>
	<brief_title>Non-interventional Multi-center Study Patients Under Routine Treatment Pulmonary Arterial Hypertension ( PAH ) With Inhaled Iloprost Using I-Neb Device Inhalation</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Adult patient ( age ≥ 18years old ) , male female Diagnosis Pulmonary Arterial Hypertension , Group I Dana Point Pulmonary Hypertension classification ( Diagnosis make discretion attend investigator , include mPAP ≥ 25 mmHg rest , measure right heart catheterization . ) The treat physician chosen initiate treatment inhale iloprost INeb device application , describe Summary Product characteristic ( SmPC ) . WHO/NYHA functional class III Willing participate study ( Informed Consent Sign ) Patients receive first inhale iloprost treatment INeb February 1st , 2013 . Any contraindication treatment Ventavis describe Summary Product characteristic ( SmPC ) Patients enrol treat inhaled iloprost INeb device application past , start observation period ( February 1st , 2013 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Ventavis</keyword>
	<keyword>Patient compliance</keyword>
</DOC>